Up-regulation of RhoGDI2 in Human Breast Cancer and Its Prognostic Implications
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Recent research has identified many genes and proteins that play specific roles in the process of systemic metastasis in various types of cancer. Rho GDP dissociation inhibitor 2 (RhoGDI2) has been shown to inhibit metastasis in human bladder cancer, but its role in breast cancer is controversial. Materials and Methods We examined the regulation and clinical significance of RhoGDI2 in Korean breast cancer patients by using proteomic approaches. Results By using a proteomic approach, we observed an increased expression of RhoGDI2 in human breast cancer tissues when compared to that of the normal breast tissues, and we validated its up-regulation in an independent cohort of 8 breast cancer patients. The clinical implication of a RhoGDI2 expression was investigated in 57 breast cancer patients by performing immunohistochemistry. RhoGDI2 did not show a significant association with the tumor size, lymph node metastasis, the histologic grade or the hormone receptor status. However, the patients with RhoGDI2-expressing tumors had significantly shorter diseasefree survival (p=0.043; hazard ratio, 3.87) and distant metastasis-free survival (p=0.039; hazard ratio, 5.15). Conclusion Our results demonstrated a potential role of RhoGDI2 as a poor prognostic marker as well as a potential therapeutic target. The pro-metastatic nature of RhoGDI2 shown in our study may indicate its organ-specific role in cancer metastasis.
Abstract
Purpose Recent research has identified many genes and proteins that play specific roles in the process of systemic metastasis in various types of cancer. Rho GDP dissociation inhibitor 2 (RhoGDI2) has been shown to inhibit metastasis in human bladder cancer, but its role in breast cancer is controversial. Materials and Methods We examined the regulation and clinical significance of RhoGDI2 in Korean breast cancer patients by using proteomic approaches. Results By using a proteomic approach, we observed an increased expression of RhoGDI2 in human breast cancer tissues when compared to that of the normal breast tissues, and we validated its up-regulation in an independent cohort of 8 breast cancer patients. The clinical implication of a RhoGDI2 expression was investigated in 57 breast cancer patients by performing immunohistochemistry. RhoGDI2 did not show a significant association with the tumor size, lymph node metastasis, the histologic grade or the hormone receptor status. However, the patients with RhoGDI2-expressing tumors had significantly shorter diseasefree survival (p=0.043; hazard ratio, 3.87) and distant metastasis-free survival (p=0.039; hazard ratio, 5.15). Conclusion Our results demonstrated a potential role of RhoGDI2 as a poor prognostic marker as well as a potential therapeutic target. The pro-metastatic nature of RhoGDI2 shown in our study may indicate its organ-specific role in cancer metastasis.
참고문헌 (23)
- Weigelt B, "Breast cancer metastasis: markers and models", Nat Rev Cancer, 5, pp.591~602 (2005)
- Fidler IJ, "The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited", Nat Rev Cancer, 3, pp.453~458 (2003)
- Eccles SA, "Metastasis: recent discoveries and novel treatment strategies", Lancet, 369, pp.1742~1757 (2007)
- Steeg PS, "Metastasis suppressors alter the signal transduction of cancer cells", Nat Rev Cancer, 3, pp.55~63 (2003)
- Steeg PS, "Metastasis suppressor genes: basic biology and potential clinical use", Clin Breast Cancer, 4, pp.51~62 (2003)
- DerMardirossian C, "GDIs: central regulatory molecules in Rho GTPase activation", Trends Cell B, 15, pp.356~363 (2005)
- Gildea JJ, "RhoGDI2 is an invasion and metastasis suppressor gene in human cancer", Cancer Res, 62, pp.6418~6423 (2002)
- Theodorescu D, "Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer", Clin Cancer Res, 10, pp.3800~3806 (2004)
- Moissoglu K, "Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases", Cancer Res, 69, pp.2838~2844 (2009)
- Harding MA, "RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation", Urol Oncol, 25, pp.401~406 (2007)
- Jiang WG, "Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers", Clin Cancer Res, 9, pp.6432~6440 (2003)
- Hu LD, "Biphasic expression of RhoGDI2 in the progression of breast cancer and its negative relation with lymph node metastasis", Oncol Rep, 17, pp.1383~1389 (2007)
- Zhang Y, "D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness", Cancer Res, 66, pp.5592~5598 (2006)
- Jung EJ, "Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer", Int J Cancer, 120, pp.2331~2338 (2007)
- Fritz G, "Rho GTPases are over-expressed in human tumors", Int J Cancer, 81, pp.682~687 (1999)
- Bouzahzah B, "Rho family GTPases regulate mammary epithelium cell growth and metastasis through distinguishable pathways", Mol Med, 7, pp.816~830 (2001)
- Jo M, "Cooperativity between the Ras- ERK and Rho-Rho kinase pathways in urokinase-type plasminogen activatorstimulated cell migration", J Biol Chem, 277, pp.12479~12485 (2002)
- Miura Y, "Regulation of morphology by rho p21 and its inhibitory GDP", GTP exchange protein (rho GDI) in Swiss 3T3 cells, 1993, pp.268, 510~515
- Leffers H, "Identification of two human Rho GDP dissociation inhibitor proteins whose overexpression leads to disruption of the actin cytoskeleton", Exp Cell Res, 209, pp.165~174 (1993)
- Leone A, "Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas", Oncogene, 8, pp.855~865 (1993)
- Nakamori S, "Expression of nucleoside diphosphate kinase", nm23 gene product in human pancreatic cancer: an association with lymph node metastasis and tumor invasion, 1993, pp.11, 151~158
- Yokoyama A, "Evaluation by multivariate analysis of the differentiation inhibitory factor nm23 as a prognostic factor in acute myelogenous leukemia and application to other hematologic malignancies", Blood, 91, pp.1845~1851 (1998)
- Elston CW, "Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up", Histopathology, 19, pp.403~410 (1991)